Philip has more than 20 years' experience writing about companies, general finance and investing matters for a variety of publications. His career has involved spells at the Investors Chronicle, where he was small companies and companies editor, Investors Week and most recently as editor of online financial news wire Sharecast. He has also contributed to a wide range of financial-focused publications on a freelance basis.
This ability to turn tumours ‘hot’ is seen as key to help a person’s immune system fight their cancer.
Tissue also now has contracts with the two largest US hospital purchase organisations (GPOs)
Protagonist will receive an upfront payment of US$50mln from Janssen with milestones, royalties and other sales milestones worth up to a further US$940mln.
Horizon’s products allow drug developers to build models of cells
The approval gives permission for Redx to initiate a Phase IB/ Phase IIA study of RXC004 in patients suffering from gastric, biliary and pancreatic cancer.
Spectrum would broaden its reach from just monoclonal antibodies to vaccines, recombinant proteins, diagnostic products and cell therapies, Repligen said.
Summit wants to improve absorption of ezutromid in patients with duchenne muscular dystrophy (DMD) through a modified diet and new formulation.
Over 1,000 plaintiffs have sued J&J in the state of Missouri but most are from outside of the state.
A round-up of some of today's broker commentary
Hargreaves Lansdown, Antofagasta, Atlantis Resources are all under the broker microscope today
M&S still a buy, Hurricane Energy, Redrow, Amec Foster Wheeler
HSBC upgrade plus Savannah Resources, Paddy Power Betfair and US election